Status:
RECRUITING
Accuracy Verification of the INVOS PM7100
Lead Sponsor:
Medtronic - MITG
Conditions:
Tissue Oxygenation
Eligibility:
All Genders
18-46 years
Brief Summary
Prospective, observational, pre-market, verification study to confirm accuracy of the INVOS 7100 system in compliance with ISO 80601-2-85:2021 standard
Detailed Description
Verify that the INVOS PM7100 system in conjunction with the INVOS Adult Sensors meets the requirements for tissue saturation accuracy.
Eligibility Criteria
Inclusion
- Healthy subjects between the ages of ≥18 to \<47 years
- Completion of a health screening for medical history by a licensed physician, nurse practitioner, or physician assistant
- Subject is a non-smoker or has not smoked within 2 days prior to the study
- Minimum weight 40kg
- BMI within range 18.0-- 35.0
- Reference tissue hemoglobin oxygen saturation over the range 50% to 85%
Exclusion
- Compromised circulation, injury, or physical malformation of fingers, hands, or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study (Note: certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized)
- Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) \[self-reported\]
- Prior known severe allergies to medical grade adhesive/tape (Band-Aid) \[self-reported\]
- Subjects taking certain medication(s) beyond birth control may be excluded from participating at the PI discretion \[self-reported\]
- Subject participation will be at the PI's discretion if they are currently participating in, or if they have recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study \[self-reported\]
- Negative Allen's test for radial and ulnar patency
- Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure \[self-reported\]
- Individuals of childbearing potential who are pregnant, who are trying to get pregnant, or who have a urine test positive for pregnancy on the day of the study and is unwilling to use effective birth control between the time of screening and study procedure, or is breastfeeding.
- Has anemia \[lab values specific for gender\]
- Has a history of sickle cell trait or thalassemia \[self-reported\]
- Has an abnormal hemoglobin electrophoresis test \[lab measurement\]
- Has a positive urine cotinine test or urine drug screen or oral ethanol test \[Point of Care (POC) testing\]
- Has a room air saturation less than 95% by pulse oximetry \[measurement by PI or delegate\]
- Has a clinically significant abnormal ECG \[assessment by PI or delegate\]
- Has a clinically significant abnormal pulmonary function test via spirometry \[assessment by PI or delegate\]
- Has a COHb greater than 3%, or MetHb greater than 2% \[measured by venous blood sample co-oximetry\]
- Has tHb \< 10 g/dl as assessed by co-oximetry during the procedure
Key Trial Info
Start Date :
September 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT07166341
Start Date
September 29 2025
End Date
April 1 2026
Last Update
December 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710